474 — Aceso Life Science Balance Sheet
0.000.00%
Last trade - 00:00
- HK$1.17bn
- HK$4.06bn
- HK$312.00m
2019 March 31st | 2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | HKAS | HKAS | HKAS | HKAS | HKAS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 1,671 | 581 | 786 | 717 | 602 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 902 | 914 | 756 | 1,065 | 744 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 2,655 | 1,634 | 2,026 | 2,266 | 2,297 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 450 | 411 | 291 | 283 | 281 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 5,555 | 5,033 | 6,165 | 6,263 | 6,301 |
Accounts Payable | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 892 | 1,049 | 1,096 | 2,451 | 2,855 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Liabilities | 2,924 | 2,543 | 3,783 | 4,261 | 4,752 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 2,631 | 2,490 | 2,382 | 2,002 | 1,549 |
Total Liabilities & Shareholders' Equity | 5,555 | 5,033 | 6,165 | 6,263 | 6,301 |
Total Common Shares Outstanding |